Lexicon Pharma (LXRX) Tops Q2 EPS by 3c
Tweet
Share
E-mail
Get Alerts LXRX Hot Sheet
Price: $2.18 +6.86%
Revenue Growth %: -78.9%
Financial Fact:
Loss from operations: -34.93M
Today's EPS Names:
OCCI, ALZN, ASPU, More
Revenue Growth %: -78.9%
Financial Fact:
Loss from operations: -34.93M
Today's EPS Names:
OCCI, ALZN, ASPU, More
Join SI Premium – FREE
Lexicon Pharma (NASDAQ: LXRX) reported Q2 EPS of ($0.13), $0.03 better than the analyst estimate of ($0.16). Revenue for the quarter came in at $234 thousand, versus $9.16 million reported last year.
For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- KB Home (KBH) Tops Q3 EPS by 16c
- UBS Reiterates Neutral Rating on Pilgrim's Pride (PPC) on 'Challenging' Near-Term Fundamentals
- Activist Corvex seeks Whitbread board seat over strategy concerns
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
